A new era of improving progression-free survival with dual blockade in postmenopausal HR+, HER2− advanced breast cancer
Author:
Publisher
Elsevier BV
Subject
Radiology Nuclear Medicine and imaging,Oncology,General Medicine
Reference64 articles.
1. Emerging targeted agents in metastatic breast cancer;Zardavas;Nat Rev Clin Oncol,2013
2. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group;Lancet,1998
3. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline;Partridge;J Clin Oncol,2014
4. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2);Cardoso;Ann Oncol,2014
5. Mechanisms of tamoxifen resistance;Ring;Endocr Relat Cancer,2004
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Addition of PI3K/AKT/mTOR inhibitors to fulvestrant for advanced HR+/HER2- breast cancer: a systematic review and meta-analysis;Future Oncology;2023-06
2. Tumor cell intrinsic and extrinsic features predict prognosis in estrogen receptor positive breast cancer;PLOS Computational Biology;2022-03-09
3. Tumor cell intrinsic and extrinsic features predicts prognosis in estrogen receptor positive breast cancer;2021-09-30
4. Anti-breast Cancer Potential of Natural and Synthetic Coumarin Derivatives;Current Topics in Medicinal Chemistry;2021-07
5. Características clínicas y pronóstico de pacientes con cáncer de mama HER2 positivo avanzado, en la era antes y después de terapias anti-HER2;Revista médica de Chile;2018-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3